WFM
RXII

Wilmington Funds Management’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Wilmington Funds Management’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$33K Hold
10,700
– – ﹤0.01% 741
2014
Q1 		$27K Hold
10,700
– – ﹤0.01% 763
2013
Q4 		$53K Buy
+10,700
New +$53K 0.01% 773

Other funds holding RXII

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Wilmington Funds Management's RXII Position: Q2 2014 in Review

Wilmington Funds Management held its GALENA BIOPHARMA INC COM (RXII) position steady in Q2 2014 at 10,700 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #741.

Wilmington Funds Management first reported a position in RXII in Q4 2013 and has held it in 3 quarters since. The position peaked at $53K in Q4 2013. 90 funds tracked by Wall St. Rank hold RXII as of Q2 2014.

  • Wilmington Funds Management held 10,700 shares of GALENA BIOPHARMA INC COM worth $33K as of Q2 2014.
  • Wilmington Funds Management left its GALENA BIOPHARMA INC COM share count unchanged in Q2 2014.
  • GALENA BIOPHARMA INC COM made up ﹤0.01% of Wilmington Funds Management's portfolio in Q2 2014, its #741 holding.
  • Wilmington Funds Management first reported a position in GALENA BIOPHARMA INC COM in Q4 2013 and has held it in 3 quarters since.
  • Wilmington Funds Management's GALENA BIOPHARMA INC COM position peaked at $53K in Q4 2013.
  • 90 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q2 2014.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.